Prime Medicine, Inc. (PRME) vs Starling Oncology, Inc. (STLN)

A side-by-side comparison of Prime Medicine, Inc. and Starling Oncology, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
Prime Medicine, Inc. logo
PRME
Prime Medicine, Inc.
$632M
$3.50HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Starling Oncology, Inc. logo
STLN
Starling Oncology, Inc.
$658M
$6.58HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

Total return — PRME vs STLN

growth of $100 · dividends reinvested · last 1y
PRME -19.5% (-19.5%/yr)STLN +8.6% (+8.6%/yr)STLN compounded faster over this window
708090100110120Start $100$80$109
PRME STLN

PRME vs STLN: by the numbers

  • •STLN is the larger company ($658M vs $632M market cap).
  • •Both run net losses; STLN's is the smaller (-6.18% vs -4613.11% net margin).

Metrics side by side

Valuation

MetricPRMESTLN
P/S ratio155.211.12
P/B ratio15.88N/A

Profitability

MetricPRMESTLN
Gross margin-58.05%15.69%
Operating margin-4498.06%-4.44%
Net margin-4613.11%-6.18%
ROE-471.98%N/A
ROIC-90.42%-31.32%

Growth (annualized)

MetricPRMESTLN
Revenue CAGR (5Y)-2.32%N/A

Go deeper

Full PRME analysisFull STLN analysisInteractive comparison tool

Dig into the metrics

Prime Medicine ROEStarling Oncology ROEPrime Medicine operating marginStarling Oncology operating marginPrime Medicine revenue growthStarling Oncology revenue growthPrime Medicine free cash flowStarling Oncology free cash flow

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.